All News

2060 articles, sorted by publication time.

Drug Development and Regulation · eu

Evaluated in Under 150 Days: Pancreatic Cancer Drug daraxonrasib Becomes First to Receive EMA Recommendation Through Phased Review

The European Medicines Agency has issued its first recommendation for marketing authorisation through phased review, bringing patients with advanced pancreatic cancer and limited treatment options closer to an oral therapy. However, further steps remain between the expert committee’s endorsement, formal authorisation and reimbursement in individual countries.

Drug Clinical Trials · global

Tumor shrinkage fails to deliver primary endpoint success: Phase 3 lung cancer setback for firmonertinib sends ArriVent shares down nearly 47%

Although the high-dose group had a higher tumor response rate, independent review did not show a significant delay in disease progression. The result is a setback for treatment hopes in lung cancer with a rare EGFR mutation and adds uncertainty to the global development of this drug licensed from China.

New Drugs and Clinical Trials · us

Exploring Intervention Before Symptoms Appear: Prion siRNA Trial Opens Enrollment to People at High Genetic Risk

The PRiSM trial is expanding to include carriers of high-risk genetic variants who have not yet developed disease, initially assessing the safety of a single dose and the extent of protein reduction. This is a step toward early intervention, but there is still a long way to go before proving it can delay disease onset.